Skip to content
Sign in

IBB · NASDAQ · ETF

iShares Biotechnology ETF (IBB) Price, Holdings & Fees

$310.22+0.81%+$2.48End-of-day price as of Oct 9, 2026

iShares Biotechnology ETF (IBB) closed at $310.22 on Oct 9, 2026, up 0.81% from the previous close of $307.74.

Share price, past year

1Y +2.08%

52-week range $278.44 – $319.85. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$310.22
Sep 30, 2026$310.78
Aug 31, 2026$303.20
Jul 31, 2026$307.51
Jun 30, 2026$288.50
May 29, 2026$295.73
Apr 30, 2026$287.61
Mar 31, 2026$300.72
Feb 27, 2026$297.18
Jan 30, 2026$296.94
Dec 31, 2025$288.83
Nov 28, 2025$299.10
Oct 31, 2025$302.58

Key statistics

Expense ratio
0.44%
as of Mar 31, 2025
Net assets
$9.1B
as of Jun 30, 2026
Holdings
252
as of Jun 30, 2026
52-week range
$278.44 – $319.85

iShares Biotechnology ETF's expense ratio is 0.44%: $44.00 a year on $10,000 invested.

Holdings

iShares Biotechnology ETF held 252 investments worth $9.09B as of Jun 30, 2026. Its largest holding was BlackRock Funds III, at 11.66% of the fund.

iShares Biotechnology ETF largest holdings by share of net assets
#Holding% of fundValue
1BlackRock Funds III11.66%$1.06B
2Vertex Pharmaceuticals, Inc.8.08%$734.32M
3Amgen, Inc.7.83%$711.36M
4Gilead Sciences, Inc.6.84%$621.79M
5Regeneron Pharmaceuticals, Inc.4.91%$445.87M
6Argenx SE3.76%$341.58M
7Alnylam Pharmaceuticals, Inc.3.12%$283.62M
8Natera, Inc.2.89%$262.68M
9Revolution Medicines, Inc.2.78%$252.66M
10Biogen, Inc.2.47%$224.09M
11Illumina, Inc.2.07%$188.03M
12Moderna, Inc.1.98%$180.31M
13Insmed, Inc.1.78%$162.20M
14BeOne Medicines Ltd.1.77%$160.77M
15Incyte Corp.1.75%$159.00M
16United Therapeutics Corp.1.73%$157.56M
17Roivant Sciences Ltd.1.43%$129.59M
18Neurocrine Biosciences, Inc.1.30%$117.98M
19Ascendis Pharma A/S1.29%$116.86M
20Genmab A/S1.12%$101.67M
21Exelixis, Inc.1.03%$93.91M
22Ionis Pharmaceuticals, Inc.1.00%$91.06M
23Bridgebio Pharma, Inc.0.98%$89.23M
24Medpace Holdings, Inc.0.95%$86.35M
25Madrigal Pharmaceuticals, Inc.0.91%$82.55M

Top 25 of 252 holdings, as of Jun 30, 2026. Percentages are of the fund's net assets.

What the fund owns

iShares Biotechnology ETF holdings by asset type
Asset type% of fund
Stocks99.88%
Cash and short-term investments12.04%
iShares Biotechnology ETF holdings by country, largest 10
Country% of fund
United States96.35%
Netherlands4.25%
Denmark2.40%
Switzerland2.17%
Bermuda1.43%
Canada1.16%
Cayman Islands0.87%
Ireland0.80%
France0.68%
Germany0.66%

Shares of net assets from the fund's N-PORT report. Funds that borrow can add up to more than 100%, with borrowing (such as repurchase agreements) shown as a negative share.

Monthly total returns

Over the 3 months to Jun 30, 2026, iShares Biotechnology ETF's total return was +12.60%, as reported to the SEC.

iShares Biotechnology ETF monthly total returns
MonthTotal return
Jun 30, 2026+10.34%
May 31, 2026+2.14%
Apr 30, 2026−0.09%

The fund's own total returns as reported to the SEC (N-PORT), including reinvested distributions. Not the sample prices above.

Fund profile

Name
iShares Biotechnology ETF
Ticker
IBB
Exchange
NASDAQ
Fund type
ETF
Trust
iSHARES TRUST
SEC series ID
S000004350
SEC CIK
0001100663
Fractional shares
Yes

Recent SEC filings

Shareholder reports and prospectuses are filed by iSHARES TRUST, the trust behind iShares Biotechnology ETF, and cover all of its funds.

Frequently asked questions

What is IBB's price?

iShares Biotechnology ETF (IBB) closed at $310.22 on Oct 9, 2026, up 0.81% from the previous close of $307.74.

What is IBB's expense ratio?

iShares Biotechnology ETF's expense ratio is 0.44%: $44.00 a year on $10,000 invested.

What does IBB hold?

iShares Biotechnology ETF held 252 investments worth $9.09B as of Jun 30, 2026. Its largest holding was BlackRock Funds III, at 11.66% of the fund. Its five largest holdings were BlackRock Funds III, Vertex Pharmaceuticals, Inc., Amgen, Inc., Gilead Sciences, Inc., Regeneron Pharmaceuticals, Inc..

How has IBB performed?

Over the 3 months to Jun 30, 2026, iShares Biotechnology ETF's total return was +12.60%, as reported to the SEC.

Sources and methodology

Holdings, net assets and monthly returns come from the fund's N-PORT filing with the SEC, as of Jun 30, 2026 (filed Aug 25, 2026). The expense ratio is from the fund's prospectus or shareholder report, as of Mar 31, 2025. Prices are generated sample data for development. Data sources and disclosures